BLI-489
- Generic Name
- BLI-489
Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00909688
Study Evaluating BLI-489 and Piperacillin in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00894439
Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00854009
Study Evaluating Single Doses of BLI-489 in Healthy Subjects
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 54
- Registration Number
- NCT00820404
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath